HRT Financial’s VistaGen Therapeutics VTGN Stock Holding History

HRT Financial’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14K	Sell	25,370 -12,215	-32%	-$7.42K	﹤0.01%	3608
2025 Q4	$24K	Buy	+37,585	New	+$136K	﹤0.01%	2967
2022 Q3	–	Sell	-629	Closed	-$16K	–	3564
2022 Q2	$16K	Sell	629 -8,947	-93%	-$316K	﹤0.01%	2632
2022 Q1	$356K	Buy	9,576 +7,641	+395%	+$333K	﹤0.01%	2112
2021 Q4	$113K	Buy	+1,935	New	+$126K	﹤0.01%	2725
2021 Q2	–	Sell	-5,582	Closed	-$356K	–	3597
2021 Q1	$356K	Buy	+5,582	New	+$373K	﹤0.01%	2012

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial's VTGN Position: Q1 2026 in Review

HRT Financial reduced its VistaGen Therapeutics (VTGN) stake by 32% in Q1 2026, selling an estimated $7.42K and leaving 25,370 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3608.

HRT Financial first reported a position in VTGN in Q1 2021 and has held it in 6 quarters since. The position peaked at $356K in Q1 2022. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

HRT Financial held 25,370 shares of VistaGen Therapeutics worth $14K as of Q1 2026.
HRT Financial sold 12,215 VistaGen Therapeutics shares in Q1 2026, an estimated $7.42K.
VistaGen Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3608 holding.
HRT Financial first reported a position in VistaGen Therapeutics in Q1 2021 and has held it in 6 quarters since.
HRT Financial's VistaGen Therapeutics position peaked at $356K in Q1 2022.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.